Call Scheduled for Wednesday, February 26, 2025, at 4:30 p.m. ET/1:30 p.m. PTSOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 ...

The U.S. stock market has been showing resilience, with the S&P 500 recently reaching an all-time high and major indices nearing record levels. In this climate, penny stocks—though often ...

In a challenging market environment, Alector Inc (NASDAQ:ALEC) stock has touched a new 52-week low, with shares plummeting to $1.59. This significant downturn reflects a broader trend for the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Schulich Medicine & Dentistry research operations lead Kristy Coleman and professor Dr. Elizabeth Finger (L to R) found intermittent dosing of oxytocin can help improve apathy symptoms in ...

Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal. SOUTH SAN FRANCISCO, Calif., Nov. 25, ...

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a ...

Alector, Inc. (NASDAQ:ALEC – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Alector in a report issued on Tuesday, January 21st.

Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed ...